Skip to main content
. 2022 Nov 16;83(3):227–236. doi: 10.1002/pros.24454

Figure 3.

Figure 3

Progression‐free survival (PFS) by first taxane or PARP inhibitor therapy, in (A) patients with ATM mutations and (B) patients with BRCA2 mutations.PARP, poly(ADP‐ribose) polymerase. [Color figure can be viewed at wileyonlinelibrary.com]